The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
Open accessAbstract
Significance: The previous lack of consensus around the use of hydroxychloroquine for COVID-19 patients underlines the need to thoroughly assess the in vivo efficacy of drugs against SARS-CoV-2. Small animal infection models, such as the hamster model, have a pivotal place herein. We here show in vivo preclinical results with favipiravir which indicate that antiviral efficacy against SARS-CoV-2 might only be achieved with a very high dose. Hydroxychloroquine, on the other hand, completely lacks antiviral activity, thus providing no scientific basis for its further use in COVID-19 patients. With this study on two key antiviral candidates, we establish the baseline for SARS-CoV-2 antiviral treatment, which will allow us to identify superior antiviral candidates in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
REED, L. J., & MUENCH, H. (1938) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118408 · Cited by 19,926
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,905
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data
Okonechnikov, K., Conesa, A., & García-Alcalde, F. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btv566 · Cited by 2,145 · cited 1×
“The mapping quality was checked using Qualimap, and the consensus whole genome sequence for the inoculated virus was generated using quantification and annotation of short reads in R (47, 48).”
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020) · Cell Discovery · doi:10.1038/s41421-020-0156-0 · Cited by 2,070
Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2
Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,911
Self-citationPathogenesis and transmission of SARS-CoV-2 in golden hamsters
Sia, S. F., Yan, L.-M., Chin, A. W. H., Fung, K., Choy, K.-T., Wong, A. Y. L., Kaewpreedee, P., Perera, R. A. P. M., Poon, L. L. M., Nicholls, J. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2342-5 · Cited by 1,358
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016638 · Cited by 1,318
Chan, J. F.-W., Zhang, A. J., Yuan, S., Poon, V. K.-M., Chan, C. C.-S., Lee, A. C.-Y., Chan, W.-M., Fan, Z., Tsoi, H.-W., Wen, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa325 · Cited by 1,058
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Choy, K.-T., Wong, A. Y.-L., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P.-H., Huang, X., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104786 · Cited by 922
Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
Rockx, B., Kuiken, T., Herfst, S., Bestebroer, T., Lamers, M. M., Oude Munnink, B. B., de Meulder, D., van Amerongen, G., van den Brand, J., Okba, N. M. A., et al. (2020) · Science · doi:10.1126/science.abb7314 · Cited by 901 · cited 2×
“In SARS-CoV-2−infected macaques (both rhesus and cynomolgus), virus levels were the highest in nasal swabs and the lungs (25, 27).”
Infection and Rapid Transmission of SARS-CoV-2 in Ferrets
Kim, Y.-I., Kim, S.-G., Kim, S.-M., Kim, E.-H., Park, S.-J., Yu, K.-M., Chang, J.-H., Kim, E. J., Lee, S., Casel, M. A. B., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.023 · Cited by 882
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852 · cited 1×
“…study already showed that, in COVID-19 patients with mild symptoms (fever and respiratory symptoms without difficulties in breathing), the clinical recovery rate at day 7 was higher in the favipiravir-treated group compared to the control group, which received treatment with arbidol (39).”
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683296 · Cited by 849
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 736
Self-citationRespiratory disease in rhesus macaques inoculated with SARS-CoV-2
Munster, V. J., Feldmann, F., Williamson, B. N., van Doremalen, N., Pérez-Pérez, L., Schulz, J., Meade-White, K., Okumura, A., Callison, J., Brumbaugh, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2324-7 · Cited by 720
Clinical characteristics of 82 cases of death from COVID-19
Zhang, B., Zhou, X., Qiu, Y., Song, Y., Feng, F., Feng, J., Song, Q., Jia, Q., & Wang, J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0235458 · Cited by 683
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D., & Kim, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00819-20 · Cited by 675 · cited 1×
“In cell culture, several repurposed drugs inhibit SARS-CoV-2 replication (5, 6).”
Spiteri, G., Fielding, J., Diercke, M., Campese, C., Enouf, V., Gaymard, A., Bella, A., Sognamiglio, P., Sierra Moros, M. J., Riutort, A. N., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.9.2000178 · Cited by 665
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 649
Self-citationStructural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Wrapp, D., De Vlieger, D., Corbett, K. S., Torres, G. M., Wang, N., Van Breedam, W., Roose, K., van Schie, L., Hoffmann, M., Pöhlmann, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.031 · Cited by 610
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
Du, Y., & Chen, X. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1844 · Cited by 418
Touret, F., Gilles, M., Barral, K., Nougairède, A., van Helden, J., Decroly, E., de Lamballerie, X., & Coutard, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-70143-6 · Cited by 393
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Delang, L., Abdelnabi, R., & Neyts, J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.03.003 · Cited by 388
Self-citationA review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
Pilkington, V., Pepperrell, T., & Hill, A. (2020) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30016-9 · Cited by 271
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
Park, S.-J., Yu, K.-M., Kim, Y.-I., Kim, S.-M., Kim, E.-H., Kim, S.-G., Kim, E. J., Casel, M. A. B., Rollon, R., Jang, S.-G., et al. (2020) · mBio · doi:10.1128/mbio.01114-20 · Cited by 185
Favipiravir (T-705) protects against Nipah virus infection in the hamster model
Dawes, B. E., Kalveram, B., Ikegami, T., Juelich, T., Smith, J. K., Zhang, L., Park, A., Lee, B., Komeno, T., Furuta, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25780-3 · Cited by 183
Tett, S., Cutler, D., Day, R., & Brown, K. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb05281.x · Cited by 177
Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology
Cleary, S. J., Pitchford, S. C., Amison, R. T., Carrington, R., Robaina Cabrera, C. L., Magnen, M., Looney, M. R., Gray, E., & Page, C. P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15143 · Cited by 174
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Wrapp, D., Vlieger, D. D., Corbett, K. S., Torres, G. M., Wang, N., Breedam, W. V., Roose, K., van Schie, L., Hoffmann, M., Pöhlmann, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.047 · Cited by 171
Viral population analysis and minority-variant detection using short read next-generation sequencing
Watson, S. J., Welkers, M. R. A., Depledge, D. P., Coulter, E., Breuer, J. M., de Jong, M. D., & Kellam, P. (2013) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0205 · Cited by 170
Self-citationQuirós-Roldán, E., Biasiotto, G., Magro, P., & Zanella, I. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104904 · Cited by 163
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
Driouich, J.-S., Cochin, M., Lingas, G., Moureau, G., Touret, F., Petit, P.-R., Piorkowski, G., Barthélémy, K., Laprie, C., Coutard, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21992-w · Cited by 158
Self-citationGarcia‐Cremades, M., Solans, B. P., Hughes, E. A., Ernest, J. P., Wallender, E. K., Aweeka, F. T., Luetkemeyer, A. F., & Savić, R. M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1856 · Cited by 119
Velde, G. V., Poelmans, J., Langhe, E. D., Hillen, A., Vanoirbeek, J. A., Himmelreich, U., & Lories, R. J. U. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.020321 · Cited by 112
Scharton, D., Bailey, K. W., Vest, Z. G., Westover, J. B., Kumaki, Y., Wettere, A. J. V., Furuta, Y., & Gowen, B. B. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.01.016 · Cited by 111
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
Irie, K., Nakagawa, A., Fujita, H., Tamura, R., Eto, M., Ikesue, H., Muroi, N., Tomii, K., & Hashida, T. (2020) · Clinical and Translational Science · doi:10.1111/cts.12827 · Cited by 95
Madelain, V., Guedj, J., Mentré, F., Nguyen, T. H. T., Jacquot, F., Oestereich, L., Kadota, T., Yamada, K., Taburet, A., de Lamballerie, X. N., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01305-16 · Cited by 75
Iterative CT Reconstruction Using Shearlet-Based Regularization
Vandeghinste, B., Goossens, B., Holen, R. V., Vanhove, C., Pižurica, A., Vandenberghe, S., & Staelens, S. G. (2013) · IEEE Transactions on Nuclear Science · doi:10.1109/tns.2013.2275994 · Cited by 67
Medical treatment options for COVID-19
Delang, L., & Neyts, J. H. (2020) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872620922790 · Cited by 58
Self-citationBoudewijns, R., Thibaut, H. J., Kaptein, S. J. F., Li, R., Vergote, V., Seldeslachts, L., Keyzer, C. D., Bervoets, L., Sharma, S., Weyenbergh, J. V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.23.056838 · Cited by 53
Self-citationPoelmans, J., Hillen, A., Vanherp, L., Govaerts, K., Maertens, J. A., Dresselaers, T., Himmelreich, U., Lagrou, K., & Velde, G. V. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.45 · Cited by 29
Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non- human primatesPreprint
Maisonnasse, P., Guedj, J., Contreras, V., Behillil, S., Solas, C., Marlin, R., Naninck, T., Pizzorno, A., Lemaître, J., Gonçalves, A., et al. (2020) · doi:10.21203/rs.3.rs-27223/v1 · Cited by 29
Self-citationStereoselective disposition of hydroxychloroquine and its metabolites in rats
Wei, Y., Nygard, G. A., Ellertson, S. L., & Khalil, S. K. W. (1995) · Chirality · doi:10.1002/chir.530070807 · Cited by 23
Lung tissue distribution of drugs as a key factor for COVID‐19 treatment
Wang, Y., & Chen, L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15102 · Cited by 20
Cited by
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R., & De Clercq, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 676
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Park, Y.-J., Pinto, D., Walls, A. C., Liu, Z., De Marco, A., Benigni, F., Zatta, F., Silacci-Fregni, C., Bassi, J., Sprouse, K. R., et al. (2022) · doi:10.1101/2022.05.08.491108 · Cited by 251
Self-citationDaems, M., Liesenborghs, L., Boudewijns, R., Simmonds, S. J., Kraisin, S., Van Wauwe, J., Cuijpers, I., Raman, J., Geuens, N., Buyten, T. V., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.964512 · Cited by 8
Self-citation
Metadata
- Authors
- Kaptein, S. J. F., Jacobs, S., Langendries, L., Seldeslachts, L., ter Horst, S., Liesenborghs, L., Hens, B., Vergote, V., Heylen, E., Barthelemy, K., Maas, E., De Keyzer, C., Bervoets, L., Rymenants, J., Van Buyten, T., Zhang, X., Abdelnabi, R., Pang, J., Williams, R., Thibaut, H. J., Dallmeier, K., Boudewijns, R., Wouters, J., Augustijns, P., Verougstraete, N., Cawthorne, C., Breuer, J., Solas, C., Weynand, B., Annaert, P., Spriet, I., Vande Velde, G., Neyts, J., Rocha-Pereira, J., & Delang, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2020-10-09
- Volume
- 117
- Issue
- 43
- Pages
- 26955-26965
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3092285496
- Cited by
- 269
- References
- 48
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.